Abstract
Study Objective
To evaluate continuance rates, bleeding patterns, and patient satisfaction with 52-mg
levonorgestrel-releasing intrauterine system (LNG-IUS) use in adolescents and young
adult women during the first 3 years of use
Design
We conducted an observational prospective study.
Setting
Family Planning Service of a tertiary hospital in Brazil
Participants
One hundred adolescents and young women aged 16-24 years.
Intervention
Insertion of 52-mg LNG-IUS for the main purpose of contraception. Follow-up visits
were conducted at 12, 24, and 36 months after insertion.
Main Outcome Measures
Continuance rates, reasons for discontinuation of the method, and women's satisfaction
and bleeding patterns
Results
Among those who were not lost to follow-up, LNG-IUS continuance rates were 89.1% (82/92),
82.9% (72/87), and 75.3% (64/85) in the first, second, and third years of use, respectively.
The main reason for discontinuation was acne, followed by expulsion of/malpositioned
LNG-IUS. Other reasons for discontinuation were irregular uterine bleeding, dysmenorrhea,
and abdominal pain. The amenorrhea rates were 50%, 54.1%, and 39% at 12, 24, and 36
months, respectively. Spotting rates increased during the first 3 years of use (20.8%,
16.7%, and 26.6%, respectively). Adolescents and young women using the LNG-IUS showed
high rates of satisfaction, with 93.9%, 100%, and 96.8% of women being very satisfied/satisfied
in the first 3 years of use. Only 2 participants who continued using the LNG-IUS reported
being very dissatisfied/dissatisfied in the third year of follow-up.
Conclusion
The LNG-IUS showed high rates of continuation and satisfaction in the first 3 years
of use in Brazilian adolescents and young adults. Most women reported a favorable
bleeding pattern.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Pediatric and Adolescent GynecologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Intended and unintended pregnancy worldwide in 2012 and recent trends.Stud Fam Plan. 2010; 41: 241-250
- Hormonal and intrauterine methods for contraception for women aged 25 years and younger.Cochrane Database Syst Rev. 2015; CD009805
- Prenatal care in Brasil.Cad Saude Publica. 2014; 30 (S1-15)
- Preventing unintended pregnancy: the Contraceptive CHOICE project in review.J Womens Health. 2015; 24: 349-353
- Contraceptive failure in the United States.Contraception. 2011; 83: 397-404
- Summary: adolescents and long-acting reversible contraception: implants and intrauterine devices.Obstet Gynecol. 2018; 131: 947-948
- Committee Opinion No 699: Adolescent pregnancy, contraception, and sexual activity.Obstet Gynecol. 2017; 129: e142-e149
- Contraception for adolescents.Pediatrics. 2014; 134: e1244-e1256
- Long-acting reversible contraception for adolescence.JAMA Pediatr. 2017; 171: 694-701
- Sexual and reproductive health care: a position paper of the Society for Adolescent Health and Medicine.J Adolesc Health. 2014; 54: 491-496
Tyson N, Berlan E, Hewit G, et al: Provision of reproductive health for teens during a pandemic. 2022. Available: https://www.naspag.org/naspag-provision-of-reproductive-health-for-teens-during-pandemic. Accessed April 26, 2022
- The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline.Hum Reprod. 2008; 23: 1338-1345
- Cost effectiveness of contraceptives in the United States.Contraception. 2009; 79: 5-14
Daniels K, Abma JC: Current contraceptive status among women aged 15-49: United States, 2015-2017 (NCHS Data Brief No 327)
- Barriers and facilitators to adolescents' use of long-acting reversible contraceptives.J Pediatr Adolesc Gynecol. 2017; 30: 18-22
- Barriers and solutions to improve adolescent intrauterine device access.J Pediatr Adolesc Gynecol. 2019; 32: S7-S13
Contracepção reversível de longa ação: São Paulo: Federação Brasileira das Associações de Ginecologia e Obstetrícia (FEBRASGO). 2016. ISSN 2525-6416 NLM WP630 Série orientações e recomendações FEBRASGO. v. 3, n.1, Nov. 2016
- Continuation rates of the 52-mg levonorgestrel-releasing intrauterine system according to the primary reason for its use.Rev Bras Ginecol Obstet. 2021; 43: 291-296
- Intrauterine contraception for adolescents aged 14-18 years: a multicenter randomized pilot study of levonorgestrel-releasing intrauterine system compared to the Copper T 380A.Contraception. 2010; 81: 123-127
- Intrauterine contraception in nulliparous women: a prospective survey.J Fam Plann Reprod Health Care. 2016; 42: 36-42
- Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system.Obstet Gynecol. 2019; 133: 63-70
- Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use.Obstet Gynecol. 2013; 122: 1214-1221
- Medical Eligibility Criteria for Contraceptive Use-5th ed 2015.WHO, Geneva2010
- Satisfaction with the intrauterine device insertion procedure among adolescent and young adult women.Obstet Gynecol. 2018; 131: 1130-1136
- Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas.Contraception. 2011; 84: e11-e16
- Young age, nulliparity, and continuation of long-acting reversible contraceptive methods.Obstet Gynecol. 2015; 126: 823-829
- Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far?.Arch Gynecol Obstet. 2017; 295: 529-541
- Association of age and parity with intrauterine device expulsion.Obstet Gynecol. 2014; 124: 718-726
- Guidelines of care for the management of acne vulgaris.J Am Acad Dermatol. 2016; 74 (945-73.e33)
- Hormonal intrauterine devices and acne.Obstet Gynecol. 2022; 139: 919-921
- Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up two years.Contraception. 2002; 65: 129-132
- Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-years study.Hum Reprod. 2014; 29: 1182-1188
Article info
Publication history
Published online: September 07, 2022
Accepted:
September 2,
2022
Received in revised form:
August 24,
2022
Received:
March 29,
2022
Footnotes
Conflict of Interest Statement: The contents of this article are the sole responsibility of the authors. ALLP have acted as consultants to Bayer HealthCare Pharmaceuticals and have received consultancy honoraria.
Identification
Copyright
© 2022 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.
